

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alcassedan, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/520,724	04/15/2005	Claes Wallen	P/1094-159	9740
2352 7590 93/23/2010 OSTROLENK FABER GERB & SOFFEN 1180 AVENUE OF THE AMERICAS			EXAMINER	
			MOULTON, ELIZABETH ROSE	
NEW YORK, NY 100368403			ART UNIT	PAPER NUMBER
			3767	•
			MAIL DATE	DELIVERY MODE
			03/23/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# Application No. 10/520,724 WALLEN, CLAES Examiner LIZABETH R. MOULTON 3767 - The MAILING DATE of this communication appears on the cover sheet with the correspondence address - Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CPR 1.136(a). In no event, however, may a reply be limitly filed after SIX (MONTHS) from the nating date of the communication after SIX (MONTHS) from the nation after SIX (MONTHS) and the sIX (MONTHS) and the sIX (MONTHS)

The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  Extensions of time may be available; under the provisions of 37 CPR 1.38(a). In no event however, may a reply be timely filed.  1 INO period for reply is specified above, the maximum statutory period will apply and will expire SN (8) MCNTHS from the mailing date of this communication.  Failure for reply within the set or carefunde period for reply will by statute, cause the application to become ABANDONED (38 U.S.C.§ 133).  Any reply received by the Office later than three months after the making date of this communication, even if timely filled, may reduce any camed patter turn adjustment. See 37 CPR 1.74(b).
Status
Responsive to communication(s) filed on 03 February 2010.  2a) This action is FINAL.  2b) This action is non-final.  3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.
Disposition of Claims
4) ⊠ Claim(s) 1-3.7-10 and 12-15 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1-3.7-10 and 12-15 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement.
Application Papers
9) ☐ The specification is objected to by the Examiner.  10) ☑ The drawing(s) flied on is/are: a) ☐ accepted or b) ☑ objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d)  11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.
Priority under 35 U.S.C. § 119
12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☐ All b) ☐ Some * c) ☐ None of:  1. ☐ Certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in Application No  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

1) ☑ Notice of Oratisperson's Patent Drawing Review (PTO-948)

2) ☐ Notice of Inflammation Disclosure Statement(s) (PTO-8508)

3) ☐ Inflammation Disclosure Statement(s) (PTO-8508)

5) ☐ Notice of Inflammation Patent Application.

5) ☐ Other:

9per Not (S) Media Date

6) ☐ Other:

Application/Control Number: 10/520,724 Page 2

Art Unit: 3767

### DETAILED ACTION

## Drawings

 The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the needle (claims 14 and 15) must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.

Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filling date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

Application/Control Number: 10/520,724 Page 3

Art Unit: 3767

# Claim Rejections - 35 USC § 103

 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

2. Claims 1-3, 7-10, and 12-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wyatt (US 5,632,735) in view of Vallancourt (US 5,122,123)

Wyatt teaches (Fig 8A): A device for injection comprising a body (65) provided with a first channel (horizontal in the figure), a first connecting component/port (62a), a second channel (within 58b) with a second connecting component/port (22), and a third connecting component/port (60a) common to the first and second channels. The second channel has air- and liquid- proof membrane (the split septum is described as preventing leaking which one of ordinary skill in the art would recognize as air- and liquid- proof) which cooperates with an injection component (M). See also infusion bag and second medical substance Col 1 line 20-45.

Wyatt does not teach an injection component with second membrane and penetrating member or a membrane lacking any preexisting openings there through.

Vallancourt teaches a valve access device (Fig 2) with a solid flexible membrane (33) and penetrating needle member (30). Vallancourt further teaches a solid membrane (27) on a Y-connector in an infusion system. The valve access device of Vallancourt may be used instead of the injection component of Wyatt. It would have been obvious

Art Unit: 3767

to one of ordinary skill in the art at the time the invention was made to use the injection component of Vallancourt instead of the injection component of Wyatt since Vallancourt maintains his access device in a sterile condition (seals 33 and 27) and to use a membrane with no preexisting openings there through as a matter of simple of substitution of two known equivalents in the art.

# Response to Arguments

 Applicant's arguments with respect to claims 1, 3-10, 12, and 13 have been considered but are moot in view of the new ground(s) of rejection.

### Conclusion

4. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Application/Control Number: 10/520,724

Art Unit: 3767

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELIZABETH R. MOULTON whose telephone number is (571)272-9970. The examiner can normally be reached on part-time R and F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/ELIZABETH R MOULTON/ Examiner, Art Unit 3767 /Kevin C. Sirmons/ Supervisory Patent Examiner, Art Unit 3767